SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32640243.
- Also identified by DOI 10.1016/j.cmet.2020.06.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent studies have shown impressive cardiovascular health benefits in individuals treated with SGLT2 inhibitors (SGLT2i) regardless of diabetic status. The underlying mechanisms driving these benefits are not well understood. Recently in Circulation, Griffin et al. (2020) reported the first human study investigating the diuretic effect of empagliflozin.
Medical subject headings
- Diabetes Mellitus, Type 2
- Heart Failure
- Sodium-Glucose Transporter 2 Inhibitors